Drug products: Amaryl®, Glimepirid 2care4, Glimepirid Actavis, Glimepirid Bluefish, Glimepirid Mylan, Glimepirid Orion, Glimepirid Sandoz, Glimepirid STADA
ATC code: A10BB12
Controlled studies on differences between men and women in glimepiride efficacy are lacking. Pharmacokinetic studies have not shown any large differences between men and women. In other studies, women treated with antidiabetics had a higher risk of hypoglycemia than men.
Population pharmacokinetic analyses have found no sex differences in the pharmacokinetics of glimepiride after adjustment for body weight [3, 4]. No studies with a clinically relevant sex analysis regarding the dosing of glimepiride have been found.
No studies with a clinically relevant sex analysis regarding the effects of glimepiride have been found.
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment in general .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
An observational retrospective study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with type 2 diabetes. Patient's sex had no significant influence on change in body weight or BMI .
Date of litterature search: 2020-07-09
Reviewed by: Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson